Ruchika Sangani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ruchika Sangani has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Divya A. Shankar
Evans Center for Implementation and Improvement Sciences, Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, United States
4 shared publications - Kari R. Gillmeyer
VA Boston Healthcare System Center for Health Optimization and Implementation Research Boston, MA
4 shared publications - Anica C. Law
The Pulmonary Center, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine , Boston, MA
3 shared publications - Nicholas A. Bosch
The Pulmonary Center Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA
3 shared publications - Allan J. Walkey
UMass Chan Medical School Division of Health Systems Sciences, Department of Medicine Worcester, Massachusetts
2 shared publications - Andreea M. Bujor
Arthritis and Autoimmune Diseases Center, Rheumatology Section, Department of Medicine, Chobanian and Avedisian School of Medicine, Boston University , Boston, MA
2 shared publications
Latest Publications
- Open Access
- 15 April 2024
- Published by Elsevier in CHEST Pulmonary
- Vol. 2 (3)
The Upper Limit of Normal Rate of Lung Function Decline in Healthy Adults in the Framingham Heart Study
- 15 April 2024
- Published by Elsevier in CHEST Pulmonary
- Vol. 2 (3)
Open AccessThe Upper Limit of Normal Rate of Lung Function Decline in Healthy Adults in the Framingham Heart Study
- 13 November 2023
- Published by Springer Nature in Lung
- Vol. 201 (6) , 565-569
A Clinical Decision Tool for Risk Stratifying Patients with Systemic Sclerosis-Related Pulmonary Hypertension
We devised a scoring system to identify patients with systemic sclerosis (SSc) at risk for pulmonary hypertension (PH) and predict all-cause mortality. Using 7 variables obtained via pulmonary function testing, echocardiography, and computed tomographic chest imaging, we applied the score to a retrospective cohort of 117 patients with SSc. There were 60 (51.3%) who were diagnosed with PH by right heart catheterization. Using a scoring threshold ≥ 0, our decision tool predicted PH with a sensitivity, specificity, and accuracy of 0.87 (95% CI 0.75, 0.94), 0.74 (95% CI 0.60, 0.84), and 0.80 (95% CI 0.72, 0.87), respectively. When adjusted for age at PH diagnosis, sex, and receipt of pulmonary arterial vasodilators, each one-point score increase was associated with an adjusted HR of 1.19 (95% CI 1.05, 1.34) for all-cause mortality. With further validation in external cohorts, our simplified clinical decision tool may better streamline earlier detection of PH in SSc.
- 13 November 2023
- Published by Springer Nature in Lung
- Vol. 201 (6) , 565-569
A Clinical Decision Tool for Risk Stratifying Patients with Systemic Sclerosis-Related Pulmonary Hypertension
We devised a scoring system to identify patients with systemic sclerosis (SSc) at risk for pulmonary hypertension (PH) and predict all-cause mortality. Using 7 variables obtained via pulmonary function testing, echocardiography, and computed tomographic chest imaging, we applied the score to a retrospective cohort of 117 patients with SSc. There were 60 (51.3%) who were diagnosed with PH by right heart catheterization. Using a scoring threshold ≥ 0, our decision tool predicted PH with a sensitivity, specificity, and accuracy of 0.87 (95% CI 0.75, 0.94), 0.74 (95% CI 0.60, 0.84), and 0.80 (95% CI 0.72, 0.87), respectively. When adjusted for age at PH diagnosis, sex, and receipt of pulmonary arterial vasodilators, each one-point score increase was associated with an adjusted HR of 1.19 (95% CI 1.05, 1.34) for all-cause mortality. With further validation in external cohorts, our simplified clinical decision tool may better streamline earlier detection of PH in SSc.
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A5990
Comparative Effectiveness of Dupilumab, Mepolizumab, and Benralizumab in Patients With Asthma
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A5990
Comparative Effectiveness of Dupilumab, Mepolizumab, and Benralizumab in Patients With Asthma
- 15 April 2023
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 207 (8) , 1089-1091
New Frontiers in Therapeutics for Interstitial Lung Diseases
- 15 April 2023
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 207 (8) , 1089-1091
New Frontiers in Therapeutics for Interstitial Lung Diseases
- Open Access
- 1 October 2022
- Published by Wiley in Pulmonary Circulation
- Vol. 12 (4) , e12117
Clinical characteristics and outcomes in pulmonary manifestations of systemic sclerosis: Contribution from pulmonary hypertension and interstitial lung disease severity
Patients with systemic sclerosis complicated by both pulmonary hypertension (SSc‐PH) and interstitial lung disease (SSc‐PH‐ILD) have poor prognosis compared to those with SSc‐PH or SSc‐ILD alone. Little is known of how ILD severity affects outcomes in those with SSc‐PH, or how PH severity affects outcomes in those with SSc‐ILD. Herein, we aimed to delineate clinical features of patients with SSc‐PH and SSc‐ILD and determine to what degree PH and ILD severity contribute to mortality in patients with SSc. We conducted parallel retrospective studies in cohorts of patients with SSc‐PH and SSc‐ILD. We categorized ILD severity by pulmonary function testing and PH severity by cardiopulmonary hemodynamics. Our primary outcome was all‐cause mortality from time of PH or ILD diagnosis for the SSc‐PH and SSc‐ILD cohorts, respectively. We calculated adjusted risks of time to all‐cause mortality using Cox proportional hazards models. In patients with SSc‐PH, severe ILD (HR: 3.54; 95% CI: 1.05, 11.99) was associated with increased hazards for all‐cause mortality. By contrast, mild and moderate ILD were not associated with increased mortality risk. In patients with SSc‐ILD, both moderate (HR: 2.65; 95% CI: 1.12, 6.31) and severe PH (HR: 6.60; 95% CI: 2.98, 14.61) were associated with increased hazards for all‐cause mortality, while mild PH was not. Through our parallel study design, the risk of all‐cause mortality increases as severity of concomitant ILD or PH worsens. Therapies that target slowing disease progression earlier in the disease course may be beneficial.
- 1 October 2022
- Published by Wiley in Pulmonary Circulation
- Vol. 12 (4) , e12117
Open AccessClinical characteristics and outcomes in pulmonary manifestations of systemic sclerosis: Contribution from pulmonary hypertension and interstitial lung disease severity
Patients with systemic sclerosis complicated by both pulmonary hypertension (SSc‐PH) and interstitial lung disease (SSc‐PH‐ILD) have poor prognosis compared to those with SSc‐PH or SSc‐ILD alone. Little is known of how ILD severity affects outcomes in those with SSc‐PH, or how PH severity affects outcomes in those with SSc‐ILD. Herein, we aimed to delineate clinical features of patients with SSc‐PH and SSc‐ILD and determine to what degree PH and ILD severity contribute to mortality in patients with SSc. We conducted parallel retrospective studies in cohorts of patients with SSc‐PH and SSc‐ILD. We categorized ILD severity by pulmonary function testing and PH severity by cardiopulmonary hemodynamics. Our primary outcome was all‐cause mortality from time of PH or ILD diagnosis for the SSc‐PH and SSc‐ILD cohorts, respectively. We calculated adjusted risks of time to all‐cause mortality using Cox proportional hazards models. In patients with SSc‐PH, severe ILD (HR: 3.54; 95% CI: 1.05, 11.99) was associated with increased hazards for all‐cause mortality. By contrast, mild and moderate ILD were not associated with increased mortality risk. In patients with SSc‐ILD, both moderate (HR: 2.65; 95% CI: 1.12, 6.31) and severe PH (HR: 6.60; 95% CI: 2.98, 14.61) were associated with increased hazards for all‐cause mortality, while mild PH was not. Through our parallel study design, the risk of all‐cause mortality increases as severity of concomitant ILD or PH worsens. Therapies that target slowing disease progression earlier in the disease course may be beneficial.